Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Update

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 272,100 shares, a growth of 11.0% from the November 15th total of 245,200 shares. Based on an average trading volume of 348,600 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.9% of the shares of the stock are short sold.

Coeptis Therapeutics Trading Down 4.4 %

COEP opened at $0.18 on Friday. The firm has a 50-day moving average price of $0.20 and a two-hundred day moving average price of $0.22. The stock has a market capitalization of $7.32 million, a PE ratio of -0.61 and a beta of -0.90. Coeptis Therapeutics has a 1-year low of $0.15 and a 1-year high of $1.02. The company has a current ratio of 0.40, a quick ratio of 0.40 and a debt-to-equity ratio of 0.03.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.